Quick Search
  Home Journal Information Current Issue Past Issues Services Contact Us  
Articles
Treatment of pediatric mild persistent asthma with low dose budesonide inhalation suspension vs. montelukast in China 
 
Treatment of pediatric mild persistent asthma with low dose budesonide inhalation suspension vs. montelukast in China
  Zhi Min Chen, De Yu Zhao, Li Xiang, Jian Guo Hong
 [Abstract] [Full Text] [PDF]   Pageviews: 1316 Times
 
Background: There are limited studies comparing budesonide inhalation suspension (BIS) with montelukast in real-world settings where treatment adherence and persistency may be suboptimal. This real-world study aims to investigate the control effectiveness of montelukast or BIS as a monotherapy in Chinese children with mild asthma.
Methods: Data were derived from a retrospective questionnaire-based analysis of 2‒14-year-old children with mild persistent asthma, who received either 500 µg of BIS (n = 153) or 4‒5 mg of montelukast (n = 240) once daily. The indicators of asthma control, the Asthma Control Test (ACT)/Childhood ACT (C-ACT) score, and the asthma-related medical costs were assessed. The differences between the two groups were compared using an unpaired t-test (normally distributed), Mann¨CWhitney U test (non-normally distributed) or chi-squared test (categorical variables).
Results: Medication compliance in the past 3-month period was better in the montelukast group than in the BIS group (P = 0.042). The montelukast group exhibited better asthma control in the past 4-week period, including lower percentages of asthmatic children with symptoms more than twice a week (P = 0.021), had night waking or night coughing (P = 0.022), or required reliever medication more than twice a week (P<0.001). The montelukast group had a lower percentage of children with an ACT/C-ACT score¡Ü19 (P=0.015). Caregivers reported a signifcantly better exercise tolerance in the children who received montelukast vs. BIS in the past 12 months (P><0.001). Signifcantly higher medical expenditures attributable to asthma in the past 12 months were observed in the BIS group vs. montelukast group (P> < 0.001). The montelukast group had a lower percentage of children with an ACT/C-ACT score ¡Ü 19 (P = 0.015). Caregivers reported a significantly better exercise tolerance in the children who received montelukast vs. BIS in the past 12 months (P<0.001). Signifcantly higher medical expenditures attributable to asthma in the past 12 months were observed in the BIS group vs. montelukast group (P> < 0.001).
Conclusion: Both treatments provided acceptable overall asthma control in children with mild persistent asthma; however, more reliever medication and more medical expenditures attributable to asthma were needed for BIS vs. montelukast in real-world settings, where factors such as compliance were also taken into account.
 
  [Articles Comment]

  title Author The End Revert Time Revert / Count

  Username:
  Comment Title: 
 
   

 

     
 
     
World Journal of Pediatric Surgery

roger vivier bags 美女 美女

Home  |  Journal Information  |  Current Issue  |  Past Issues  |  Journal Information  |  Contact Us
Children's Hospital, Zhejiang University School of Medicine, China
Copyright 2007  www.wjpch.com  All Rights Reserved Designed by eb